title: State-of-the-art 2003 on PKU gene therapy.
abstract: Phenylketonuria (or PKU) is a well-known and widespread genetic disease for which many countries perform newborn screening, and life-long dietary restriction is still the ultimate and effective therapy. However, the diet is complicated, unpalatable, and expensive. The long-term effects of diet discontinuation in adults, except for the serious adverse effects of maternal hyperphenylalaninemia upon the developing fetus, have not been systematically studied, but cognitive decline and neurologic abnormalities have been anecdotally reported. Thus, alternative approaches for PKU therapy, including gene therapy, must be further explored. Here we summarize past present nonviral and viral gene transfer approaches, both in vitro studies and preclinical animal trials, to delivering the PAH gene into liver or other organs as potential alternatives to life-long phenylalanine-restricted dietary therapy.
authors.affiliation: Department of Pediatrics, University of Zürich, Steinwiesstrasse 75, CH-8032, Zürich, Switzerland.
authors.forename: Zhaobing
authors.initials: Z
authors.lastname: Ding
authors.forename: Cary O
authors.initials: CO
authors.lastname: Harding
authors.forename: Beat
authors.initials: B
authors.lastname: Thöny
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008099:Liver / Q000378:metabolism; D051379:Mice; D010651:Phenylalanine Hydroxylase / Q000235:genetics; D010661:Phenylketonurias / Q000628:therapy*
chemical_list: D010651:Phenylalanine Hydroxylase